Biogen (BIIB) Stock Forecast & Price Target

BIIB$253.40+2.92 +1.17%
Drug Manufacturers - GeneralLarge Cap
Compare
Market cap$37.46BEnterprise value$44.11BRevenue (TTM)$10.30BMarket positionTop 25%

Score

34
Bearish
Value
40
Quality
36
Growth
26

Biogen Inc. price target

BIIB
Low$175.00
Average$255.00
High$300.00
Upside vs current price+0.6%

The average target of $255.00 is +0.6% versus the current BIIB price of $253.40.

Biogen Inc. analyst ratings

RatingAnalysts
Strong buy4
Buy21
Hold10
Sell1
Strong sell0
ConsensusBuy

36 analysts cover BIIB.

Biogen Inc. EPS and revenue estimates

Published annual figures for BIIB on this page are 2026 EPS $12.47, 2027 EPS $16.27. Coverage under three analysts is omitted.

Fiscal yearEPS estimateRevenue estimate
2026$12.47$10.58B
2027$16.27$10.78B

Is Biogen Inc. a buy or sell?

Of the 36 analysts covering Biogen Inc., 25 rate it a buy (4 strong buy and 21 buy), 10 rate it a hold, and 1 rates it a sell (1 sell and 0 strong sell).

The BIIB consensus label is Buy, beside 25 buy-side ratings and 1 sell-side ratings.

The average target of $255.00 implies +0.6% versus the current price of $253.40.

The BIIB rating block is 36 published views with a Buy label. It does not tell you whether to buy or sell.

Reading the Biogen Inc. forecast

A wide spread is the story on BIIB. Targets run from $175.00 to $300.00, with $255.00 as the average.

The gap from the $253.40 price to the BIIB average is +0.6%.

The BIIB rating mix is lopsided rather than split: 25 of 36 analysts are on the buy side, 10 are at hold, and 1 is on the sell side, and the published consensus is Buy.

the Biogen Inc. has seen more upgrades (3) than downgrades (0) lately.

Month by month, the BIIB average target is higher ($268.11) than the quarterly average ($259.64).

the Biogen Inc. is followed by 36 analysts, so the range matters more than any one target.

Biogen Inc. forecast questions

What is the BIIB price target?

The published range for BIIB is $175.00 to $300.00, with an average of $255.00. That average is +0.6% versus the current price of $253.40.

Is Biogen Inc. a buy or sell?

Of the 36 analysts covering Biogen Inc., 25 rate it a buy, 10 rate it a hold, and 1 rates it a sell. The consensus is Buy, leaving BIIB at 25 buy ratings, 10 holds, and 1 sells.

What is the EPS estimate for Biogen Inc.?

Analyst EPS estimates for Biogen Inc.: 2026 $12.47, 2027 $16.27.

What is the revenue estimate for Biogen Inc.?

Analyst revenue estimates for Biogen Inc.: 2026 $10.58B, 2027 $10.78B.

How many analysts cover BIIB?

36 analysts cover BIIB. Their consensus on BIIB is Buy, across those 36.

BIIB price $253.40 +2.92 +1.17%

Insights · Forecast · Financials · Learn

Stocklytics home · Screener